Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 28, 2025 08:00 ET | Source: Spero Therapeutics, Inc. CAMBRIDGE, Mass.,…
PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint…
